SEQUENTIAL USE OF MTOR-INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

被引：0
|
作者：
Busch, J. [1 ]
Kempkensteffen, C. [1 ]
Gruenwald, V [2 ]
Weinkauf, L. [1 ]
Hinz, S. [1 ]
Magheli, A. [1 ]
Miller, K. [1 ]
Johannsen, M. [1 ]
Weikert, S. [1 ]
机构：
[1] Charite, Dept Urol, D-13353 Berlin, Germany
[2] Hannover Med Sch, Clin Haematol Haemostaseol Oncol & Stem Cell Tran, Hannover, Germany
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2011年 / 10卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(11)60713-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [1] SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT
    Weikert, S.
    Kempkensteffen, C.
    Zimmermann, K.
    Gruenwald, V.
    Floercken, A.
    Westermann, J.
    Miller, K.
    Keilholz, U.
    Johannsen, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 63 - 63
  • [2] Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
    Weikert, Steffen
    Kempkensteffen, Carsten
    Busch, Jonas
    Johannsen, Manfred
    Gruenwald, Viktor
    Zimmermann, Kaja
    Floercken, Anne
    Westermann, Joerg
    Weinkauf, Lisa
    Miller, Kurt
    Keilholz, Ulrich
    WORLD JOURNAL OF UROLOGY, 2013, 31 (04) : 805 - 809
  • [3] Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
    Steffen Weikert
    Carsten Kempkensteffen
    Jonas Busch
    Manfred Johannsen
    Viktor Grünwald
    Kaja Zimmermann
    Anne Flörcken
    Jörg Westermann
    Lisa Weinkauf
    Kurt Miller
    Ulrich Keilholz
    World Journal of Urology, 2013, 31 : 805 - 809
  • [4] Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
    Au, Trang H.
    Bailey, Erin B.
    Patel, Shiven B.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] Antitumor activity of sequential treatment with tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Fenner, M.
    Seidel, C.
    Heuser, M.
    Ganser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's)
    Khasawneh, M. F.
    Unnithan, J.
    Choueiri, T.
    Rini, B.
    Dreicer, R.
    Garcia, J.
    Wood, L.
    Elson, P.
    Bukowski, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)
    Calvani, N.
    Chetri, M. C.
    Cinefra, M.
    D'Amico, M.
    Fedele, P.
    Marino, M.
    Mazzoni, E.
    Nacci, A.
    Orlando, L.
    Rizzo, P.
    Schiavone, P.
    Sponziello, F.
    Cinieri, S.
    CANCER TREATMENT REVIEWS, 2010, 36 : S99 - S99
  • [8] USE OF TYROSINE KINASE INHIBITORS (TKI) IN HAEMODIALYTIC METASTATIC RENAL CELL CARCINOMA PATIENTS
    Sabbatini, R.
    Porta, C.
    Procopio, G.
    Ferrari, A.
    Conte, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [9] Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
    Kumano, Masafumi
    Miyake, Hideaki
    Harada, Ken-ichi
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [10] SEQUENTIAL USE OF MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA FOLLOWING FAILURE OF TYROSINE KINASE INHIBITORS
    Harada, Ken-ichi
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2014, 191 (04): : E641 - E642
12345